Conversely, a multi-cohort retrospective study across ten cancer types has suggested that JMJD5 may function as a tumour suppressor; high expression levels were associated with a lower risk of death in pancreatic and liver cancer cohorts, while low JMJD5 levels correlated with poorer survival outcomes [116]. The gene discussed is KDM8; the disease is neoplasm.